Form 4 Filing for Aptose Biosciences Inc.

This filing details transactions by Mark D. Vincent, a former director of Aptose Biosciences Inc. On June 13, 2026, Vincent disposed of 14 Common Shares for $1.72 per share, as part of a business arrangement agreement where Hammi Pharmaceuticals Co. Ltd. acquired all outstanding shares of the issuer. On June 30, 2026, Vincent also reported the disposition of various stock options, including Director Stock Options and Director Option Grants, totaling a significant number of underlying common shares. These options had varying vesting schedules and expiration dates, with exercise prices ranging from $0.66 to $6.91. The transactions are noted as being subject to adjustments due to previous reverse stock splits. The filing is made on Form 4 and is not subject to Section 16 reporting requirements.